康惠製藥(603139.SH):放棄控股子公司股權轉讓優先購買權
格隆匯6月7日丨康惠製藥(603139.SH)公佈,公司控股子公司山東友幫生化科技有限公司(稱“山東友幫”)2021-2023年連續三年未實現承諾業績,山東友幫原股東來新勝應向公司補償26,909.42萬元。
來新勝擬將其所持山東友幫49%股權轉讓給弘福醫藥有限公司(稱“弘福醫藥”或“受讓方”),轉讓價款為1,427萬元,其中,830萬元由弘福醫藥直接支付給公司用於償還來新勝業績補償款,補償款不足部分尚有26,079.42萬元,公司要求來新勝繼續履行補償義務,若來新勝不予履行補償義務時,公司將通過司法途徑對來新勝進行追償。公司放棄對山東友幫49%股權的優先購買權。本次放棄優先購買權後,公司仍持有山東友幫51%股權,公司合併報表範圍未發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.